Corcept Therapeutics (CORT) Competitors $70.86 -2.24 (-3.06%) Closing price 04:00 PM EasternExtended Trading$71.66 +0.80 (+1.12%) As of 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CORT vs. ANVS, RPRX, JAZZ, PRGO, SUPN, PCRX, NKTR, OMER, ASMB, and CPIXShould you be buying Corcept Therapeutics stock or one of its competitors? The main competitors of Corcept Therapeutics include Annovis Bio (ANVS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), and Cumberland Pharmaceuticals (CPIX). These companies are all part of the "medical" sector. Corcept Therapeutics vs. Its Competitors Annovis Bio Royalty Pharma Jazz Pharmaceuticals Perrigo Supernus Pharmaceuticals Pacira BioSciences Nektar Therapeutics Omeros Assembly Biosciences Cumberland Pharmaceuticals Annovis Bio (NYSE:ANVS) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability. Do insiders & institutionals believe in ANVS or CORT? 15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 20.8% of Annovis Bio shares are held by company insiders. Comparatively, 20.8% of Corcept Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer ANVS or CORT? Annovis Bio presently has a consensus price target of $18.00, suggesting a potential upside of 577.20%. Corcept Therapeutics has a consensus price target of $138.25, suggesting a potential upside of 95.10%. Given Annovis Bio's higher probable upside, research analysts plainly believe Annovis Bio is more favorable than Corcept Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annovis Bio 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00Corcept Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ANVS or CORT more profitable? Corcept Therapeutics has a net margin of 19.33% compared to Annovis Bio's net margin of 0.00%. Corcept Therapeutics' return on equity of 20.40% beat Annovis Bio's return on equity.Company Net Margins Return on Equity Return on Assets Annovis BioN/A -300.56% -193.50% Corcept Therapeutics 19.33%20.40%16.64% Does the media favor ANVS or CORT? In the previous week, Corcept Therapeutics had 15 more articles in the media than Annovis Bio. MarketBeat recorded 15 mentions for Corcept Therapeutics and 0 mentions for Annovis Bio. Corcept Therapeutics' average media sentiment score of 0.97 beat Annovis Bio's score of 0.00 indicating that Corcept Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Annovis Bio Neutral Corcept Therapeutics Positive Which has preferable valuation and earnings, ANVS or CORT? Corcept Therapeutics has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnovis BioN/AN/A-$24.59M-$2.16-1.23Corcept Therapeutics$675.04M11.13$141.21M$1.1661.09 Which has more risk & volatility, ANVS or CORT? Annovis Bio has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. SummaryCorcept Therapeutics beats Annovis Bio on 11 of the 14 factors compared between the two stocks. Get Corcept Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CORT vs. The Competition Export to ExcelMetricCorcept TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.75B$2.46B$5.54B$9.41BDividend YieldN/A1.80%3.75%4.03%P/E Ratio61.094.4521.0120.09Price / Sales11.13709.89433.8199.01Price / Cash58.86164.7736.1658.27Price / Book10.925.008.125.65Net Income$141.21M$30.99M$3.25B$257.91M7 Day Performance-1.42%1.69%0.97%2.09%1 Month Performance-0.53%9.20%7.36%11.13%1 Year Performance112.86%-1.25%31.31%18.40% Corcept Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CORTCorcept Therapeutics4.7921 of 5 stars$70.86-3.1%$138.25+95.1%+119.9%$7.75B$675.04M61.09300ANVSAnnovis Bio1.5854 of 5 stars$2.39+1.3%$18.00+653.1%-77.4%$46.57MN/A-1.113RPRXRoyalty Pharma4.9716 of 5 stars$35.59-2.1%$47.33+33.0%+26.2%$20.01B$2.26B19.2480News CoveragePositive NewsDividend AnnouncementJAZZJazz Pharmaceuticals4.8116 of 5 stars$107.60-1.7%$184.00+71.0%+6.3%$6.51B$4.07B14.352,800Analyst ForecastPRGOPerrigo4.6253 of 5 stars$26.74-1.7%$33.00+23.4%-2.0%$3.68B$4.37B-20.418,379News CoveragePositive NewsSUPNSupernus Pharmaceuticals2.3694 of 5 stars$31.45-1.7%$36.00+14.5%+16.0%$1.76B$661.82M28.33580Positive NewsPCRXPacira BioSciences3.1024 of 5 stars$23.22flat$26.44+13.9%+6.2%$1.07B$700.97M-10.18720NKTRNektar Therapeutics4.0678 of 5 stars$23.47-5.2%$84.17+258.6%+22.6%$291.26M$98.43M-2.45220Analyst RevisionHigh Trading VolumeOMEROmeros3.7837 of 5 stars$3.08-3.8%$18.00+484.4%-33.1%$180.46MN/A-1.16210Positive NewsAnalyst RevisionGap UpASMBAssembly Biosciences3.7919 of 5 stars$18.56+2.3%$33.00+77.8%+27.1%$141.80M$28.52M-2.98100Trending NewsCPIXCumberland Pharmaceuticals0.8866 of 5 stars$3.04-3.5%N/A+152.4%$45.48M$37.87M-12.1680Trending News Related Companies and Tools Related Companies Annovis Bio Competitors Royalty Pharma Competitors Jazz Pharmaceuticals Competitors Perrigo Competitors Supernus Pharmaceuticals Competitors Pacira BioSciences Competitors Nektar Therapeutics Competitors Omeros Competitors Assembly Biosciences Competitors Cumberland Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CORT) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corcept Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Corcept Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CORT Stock Alerts